Literature DB >> 25186301

CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.

Elena Senís1, Chronis Fatouros, Stefanie Große, Ellen Wiedtke, Dominik Niopek, Ann-Kristin Mueller, Kathleen Börner, Dirk Grimm.   

Abstract

Its remarkable ease and efficiency make the CRISPR (clustered regularly interspaced short palindromic repeats) DNA editing machinery highly attractive as a new tool for experimental gene annotation and therapeutic genome engineering in eukaryotes. Here, we report a versatile set of plasmids and vectors derived from adeno-associated virus (AAV) that allow robust and specific delivery of the two essential CRISPR components - Cas9 and chimeric g(uide)RNA - either alone or in combination. All our constructs share a modular design that enables simple and stringent guide RNA (gRNA) cloning as well as rapid exchange of promoters driving Cas9 or gRNA. Packaging into potent synthetic AAV capsids permits CRISPR delivery even into hard-to-transfect targets, as shown for human T-cells. Moreover, we demonstrate the feasibility to direct Cas9 expression to or away from hepatocytes, using a liver-specific promoter or a hepatic miRNA binding site, respectively. We also report a streamlined and economical protocol for detection of CRISPR-induced mutations in less than 3 h. Finally, we provide original evidence that AAV/CRISPR vectors can be exploited for gene engineering in vivo, as exemplified in the liver of adult mice. Our new tools and protocols should foster the broad application of CRISPR technology in eukaryotic cells and organisms, and accelerate its clinical translation into humans.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  AAV; CRISPR; Gene editing; Genome engineering; Viral vectors

Mesh:

Substances:

Year:  2014        PMID: 25186301     DOI: 10.1002/biot.201400046

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  103 in total

1.  Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic.

Authors:  Edward M Kennedy; Anand V R Kornepati; Adam L Mefferd; Joy B Marshall; Kevin Tsai; Hal P Bogerd; Bryan R Cullen
Journal:  Methods       Date:  2015-08-17       Impact factor: 3.608

2.  Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells.

Authors:  Jia Liu; Thomas Gaj; Yifeng Yang; Nan Wang; Sailan Shui; Sojung Kim; Chidananda Nagamangala Kanchiswamy; Jin-Soo Kim; Carlos F Barbas
Journal:  Nat Protoc       Date:  2015-10-22       Impact factor: 13.491

Review 3.  In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.

Authors:  Rubul Mout; Moumita Ray; Yi-Wei Lee; Federica Scaletti; Vincent M Rotello
Journal:  Bioconjug Chem       Date:  2017-03-17       Impact factor: 4.774

4.  Hitting the target without pulling the trigger.

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Mol Ther       Date:  2015-01       Impact factor: 11.454

Review 5.  Delivery technologies for genome editing.

Authors:  Hao Yin; Kevin J Kauffman; Daniel G Anderson
Journal:  Nat Rev Drug Discov       Date:  2017-03-24       Impact factor: 84.694

Review 6.  Applications of CRISPR/Cas9 in retinal degenerative diseases.

Authors:  Ying-Qian Peng; Luo-Sheng Tang; Shigeo Yoshida; Ye-Di Zhou
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

7.  Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.

Authors:  Zeming Chen; Fuyao Liu; Yanke Chen; Jun Liu; Xiaoying Wang; Ann T Chen; Gang Deng; Hongyi Zhang; Jie Liu; Zhangyong Hong; Jiangbing Zhou
Journal:  Adv Funct Mater       Date:  2017-10-16       Impact factor: 18.808

8.  Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.

Authors:  Chang Xie; Ya-Ping Zhang; Lu Song; Jie Luo; Wei Qi; Jialu Hu; Danbo Lu; Zhen Yang; Jian Zhang; Jian Xiao; Bin Zhou; Jiu-Lin Du; Naihe Jing; Yong Liu; Yan Wang; Bo-Liang Li; Bao-Liang Song; Yan Yan
Journal:  Cell Res       Date:  2016-08-30       Impact factor: 25.617

Review 9.  Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There?

Authors:  Nandini Agarwal; Branimir Popovic; Nicole J Martucci; Nicolas A Fraunhoffer; Alejandro Soto-Gutierrez
Journal:  Gene Expr       Date:  2018-08-24

Review 10.  In vivo epigenome editing and transcriptional modulation using CRISPR technology.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  Transgenic Res       Date:  2018-10-04       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.